In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

France eliminates clinical trial application fees

This article was originally published in SRA

Researchers in France no longer have to pay fees to register clinical trials with AFSSAPS, the national medicines regulator1. A provision in the country’s budget for this year took effect on 1 January, eliminating two fees that cost sponsors up to €6,000 per trial application. The changes are aimed at simplifying procedures.

Payment of the fees became a condition for filing clinical trial applications in 2006. The agency imposed a variable fee based on the complexity of the application and it collected an additional fee on behalf of the ethics committee responsible for overseeing the trial. The fees were payable for all clinical trials and treatment studies, and for projects involving the handling of human tissues and other biological samples. Researchers in public institutions and in the nonprofit sector were charged at 10% of the standard rate.

The agency notes that for all clinical research (with the exception of human medicines), sponsors must obtain a registration number from AFSSAPS before submitting their applications. Sponsors of trials for human medicines have to obtain their registration number from the European Medicines Agency’s clinical trials database, EudraCT.

The 2009 finance legislation repeals AFSSAPS’ 25 August 2006 order on clinical research fees.

References

1. AFSSAPS press release, 1 January 2009, http://agmed.sante.gouv.fr/htm/3/rcb/indrcb.htm

Latest Headlines
See All
UsernamePublicRestriction

Register

MT038424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel